224 related articles for article (PubMed ID: 20332357)
1. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
Rosenstock J; Klaff LJ; Schwartz S; Northrup J; Holcombe JH; Wilhelm K; Trautmann M
Diabetes Care; 2010 Jun; 33(6):1173-5. PubMed ID: 20332357
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
4. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
[TBL] [Abstract][Full Text] [Related]
5. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.
Apovian CM; Bergenstal RM; Cuddihy RM; Qu Y; Lenox S; Lewis MS; Glass LC
Am J Med; 2010 May; 123(5):468.e9-17. PubMed ID: 20399326
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
[TBL] [Abstract][Full Text] [Related]
7. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
Dushay J; Gao C; Gopalakrishnan GS; Crawley M; Mitten EK; Wilker E; Mullington J; Maratos-Flier E
Diabetes Care; 2012 Jan; 35(1):4-11. PubMed ID: 22040840
[TBL] [Abstract][Full Text] [Related]
8. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Kelly AS; Bergenstal RM; Gonzalez-Campoy JM; Katz H; Bank AJ
Cardiovasc Diabetol; 2012 Jun; 11():64. PubMed ID: 22681705
[TBL] [Abstract][Full Text] [Related]
9. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
10. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
11. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
13. Exenatide as a novel weight loss modality in patients without diabetes.
Moreno JL; Willett KC; Desilets AR
Ann Pharmacother; 2012 Dec; 46(12):1700-6. PubMed ID: 23191935
[TBL] [Abstract][Full Text] [Related]
14. Alterations in energy balance following exenatide administration.
Bradley DP; Kulstad R; Racine N; Shenker Y; Meredith M; Schoeller DA
Appl Physiol Nutr Metab; 2012 Oct; 37(5):893-9. PubMed ID: 22735035
[TBL] [Abstract][Full Text] [Related]
15. Potential use of exenatide for the treatment of obesity.
Folli F; Guardado Mendoza R
Expert Opin Investig Drugs; 2011 Dec; 20(12):1717-22. PubMed ID: 22017240
[TBL] [Abstract][Full Text] [Related]
16. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial.
Lian F; Li G; Chen X; Wang X; Piao C; Wang J; Hong Y; Ba Z; Wu S; Zhou X; Lang J; Liu Y; Zhang R; Hao J; Zhu Z; Li H; Fang Liu H; Cao A; Yan Z; An Y; Bai Y; Wang Q; Zhen Z; Yu C; Wang CZ; Yuan CS; Tong X
J Clin Endocrinol Metab; 2014 Feb; 99(2):648-55. PubMed ID: 24432995
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
19. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.
Kelly AS; Metzig AM; Rudser KD; Fitch AK; Fox CK; Nathan BM; Deering MM; Schwartz BL; Abuzzahab MJ; Gandrud LM; Moran A; Billington CJ; Schwarzenberg SJ
Obesity (Silver Spring); 2012 Feb; 20(2):364-70. PubMed ID: 22076596
[TBL] [Abstract][Full Text] [Related]
20. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
